News >

Apatinib Shows Potential in Advanced Sarcoma

Jason Harris
Published: Thursday, May 11, 2017

Chinese researchers have concluded that the oral VEGFR2 inhibitor apatinib (YN968D1) demonstrated efficacy with tolerable toxicity in a small study of patients with stage IV sarcoma, according to results published in Oncotarget.

“Our study provides supporting evidence that apatinib exhibits objective efficacy in stage IV sarcomas with manageable toxicity,” wrote Li et al. “Therefore, random controlled trials based on these data are warranted to further evaluate the apatinib activity in advanced sarcomas.
Li F, Lio Z, Zhao J, et al. Efficacy and safety of apatinib in stage IV sarcomas: experience of a major sarcoma center in China [published online March 16, 2017]. Oncotarget. doi:10.18632/oncotarget.16293.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication